Medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.



Reporting of side effects

The safety of our patients is very important to us. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

By reporting any side effects that you may experience, you are helping to provide more information on the safety of our medicines. Report a possible side-effect to AstraZeneca by 'report side-effect' below. If you are based in the UK, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.



Oncology

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Calquence

acalabrutinib

Enhertu

trastuzumab deruxtecan

Faslodex

fulvestrant

Imfinzi

durvalumab

Iressa

gefitinib

Koselugo

selumetinib

Lumoxiti

moxetumomab pasudotox-tdfk

Lynparza

olaparib

Orpathys

savolitinib

Tagrisso

osimertinib

Zoladex

goserelin acetate implant

Cardiovascular, Renal & Metabolism

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Brilinta/Brilique

ticagrelor

Bydureon/Bydureon,BCise

exenatide XR injectable suspension

Byetta

exenatide injection

Crestor

rosuvastatin calcium

Farxiga/Forxiga

dapagliflozin

Komboglyze/Kombiglyze XR

saxagliptin/metformin

Lokelma

sodium zirconium cyclosilicate

Onglyza

saxagliptin

Roxadustat

Qtern

dapagliflozin/saxagliptin

Xigduo/Xigduo XR

dapagliflozin/metformin

Respiratory & Immunology

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Bevespi Aerosphere

glycopyrronium/formoterol

Breztri Aerosphere (PT010)

budesonide/glycopyrrolate/formoterol

Daliresp/Daxas

roflumilast

Duaklir/Brimica

aclidinium/formoterol

Fasenra

benralizumab

Pulmicort

budesonide

Saphnelo

anifrolumab

Symbicort 

budesonide/formoterol

Tudorza/Eklira/Bretaris

aclidinium

Rare Disease

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Andexxa/Ondexxya

andexanet alfa

Kanuma

sebelipase alfa

Soliris

eculizumab

Strensiq

asfotase alfa

Ultomiris

ravulizumab


Early access to AstraZeneca investigational medicinal products

We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.

 


Veeva ID: Z4-42563
Date of preparation: February 2022